TY - JOUR
T1 - Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease
AU - Feldt-Rasmussen, Ulla
AU - Abs, Roger
AU - Bengtsson, Bengt-Ake
AU - Bennmarker, Helge
AU - Bramnert, Margareta
AU - Hernberg-Ståhl, Elizabeth
AU - Monson, John P
AU - Westberg, Björn
AU - Wilton, Patrick
AU - Wüster, Christian
AU - KIMS International Study Board of KIMS Study Group
PY - 2002/1
Y1 - 2002/1
N2 - OBJECTIVE: To compare baseline characteristics in adult patients with growth hormone (GH) deficiency (GHD) who had previously been treated for Cushing's disease or acromegaly with data from patients with GHD of other aetiologies. To study the effects of GH therapy in those patients who had completed at least 6 months of GH replacement.DESIGN: Data from a large outcomes research database (KIMS (Pharmacia International Metabolic Database)).METHODS: 135 patients were identified with previous Cushing's disease, 40 had had acromegaly, and 1392 had GHD of other aetiologies. The number of additional hormone deficiencies, and the mean age of the patients were similar in the three groups. Similar proportions of patients in each group were treated using surgery, but radiotherapy was used more often in patients with acromegaly than those with other diagnoses.RESULTS: At baseline, the prevalence of diabetes mellitus and hypertension were significantly higher in the group treated for Cushing's disease, and the prevalence of stroke was significantly higher in the group treated for acromegaly. The incidence of coronary heart disease and claudication were similar in all three groups. Patients treated for Cushing's disease had lower bone mineral density and suffered fractures more often than other GHD adults. Body mass index, waist-hip ratio, serum concentrations of lipids and standard deviation scores of serum concentrations of insulin-like-growth factor-I were similar in the three groups. The dose of GH administered was comparable in the three groups and the effects of GH replacement on waist circumference, blood pressure and quality of life were also similar across the groups. The numbers and types of adverse events reported were not different between the groups.CONCLUSIONS: These data suggest that the characteristics of patients in these diagnostic groups depend on the primary disease which resulted in GHD, and that the clinical expression of GHD does not differ between the groups. Patients with previous hypercortisolism showed more long-term effects of their disease, such as diabetes mellitus, hypertension and fractures. A benefit from GH replacement was evident in patients previously treated for acromegaly and Cushing's disease particularly in relation to quality of life.
AB - OBJECTIVE: To compare baseline characteristics in adult patients with growth hormone (GH) deficiency (GHD) who had previously been treated for Cushing's disease or acromegaly with data from patients with GHD of other aetiologies. To study the effects of GH therapy in those patients who had completed at least 6 months of GH replacement.DESIGN: Data from a large outcomes research database (KIMS (Pharmacia International Metabolic Database)).METHODS: 135 patients were identified with previous Cushing's disease, 40 had had acromegaly, and 1392 had GHD of other aetiologies. The number of additional hormone deficiencies, and the mean age of the patients were similar in the three groups. Similar proportions of patients in each group were treated using surgery, but radiotherapy was used more often in patients with acromegaly than those with other diagnoses.RESULTS: At baseline, the prevalence of diabetes mellitus and hypertension were significantly higher in the group treated for Cushing's disease, and the prevalence of stroke was significantly higher in the group treated for acromegaly. The incidence of coronary heart disease and claudication were similar in all three groups. Patients treated for Cushing's disease had lower bone mineral density and suffered fractures more often than other GHD adults. Body mass index, waist-hip ratio, serum concentrations of lipids and standard deviation scores of serum concentrations of insulin-like-growth factor-I were similar in the three groups. The dose of GH administered was comparable in the three groups and the effects of GH replacement on waist circumference, blood pressure and quality of life were also similar across the groups. The numbers and types of adverse events reported were not different between the groups.CONCLUSIONS: These data suggest that the characteristics of patients in these diagnostic groups depend on the primary disease which resulted in GHD, and that the clinical expression of GHD does not differ between the groups. Patients with previous hypercortisolism showed more long-term effects of their disease, such as diabetes mellitus, hypertension and fractures. A benefit from GH replacement was evident in patients previously treated for acromegaly and Cushing's disease particularly in relation to quality of life.
KW - Acromegaly/complications
KW - Adult
KW - Aged
KW - Bone Density
KW - Cushing Syndrome/complications
KW - Databases, Factual
KW - Diabetes Complications
KW - Diabetes Mellitus/epidemiology
KW - Female
KW - Growth Hormone/therapeutic use
KW - Hormones/blood
KW - Human Growth Hormone/deficiency
KW - Humans
KW - Hypertension/complications
KW - Hypopituitarism/drug therapy
KW - Male
KW - Middle Aged
KW - Quality of Life
KW - Radioimmunoassay
KW - Stroke/epidemiology
KW - Treatment Outcome
U2 - 10.1530/eje.0.1460067
DO - 10.1530/eje.0.1460067
M3 - Journal article
C2 - 11751070
SN - 0804-4643
VL - 146
SP - 67
EP - 74
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 1
ER -